Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$235.0K+267.19%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Angulo
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 18
- Beta
- 1.06
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.95
Financials
Revenue
$235.0K+267.2%Net Income
$7.40MEBITDA
$7.40MFree Cash Flow
$-14.88MEPS (diluted)
$0.63Shares Outstanding (diluted)
11.82M+404.8%Operating Expenses
$8.01MCash & Debt
$54.08MReturn of Capital
$2.54MRevenue by Segment (annual)
$20.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $20.60M | $-8.61M | $-1.38 |
| 2024 | $3.75M | $-21.29M | $-3.51 |
| 2023 | $140.14M | $67.04M | $11.21 |
| 2022 | $5.09M | $-62.81M | $-11.79 |
| 2021 | $13.16M | $-32.87M | $-9.97 |
| 2020 | $0.00 | $-55.19M | $-41.18 |
| 2019 | $121.0K | $-53.71M | $-76.62 |
| 2018 | $257.0K | $-12.47M | $-22.73 |
| 2017 | $257.0K | $-25.06M | $-75.20 |
| 2016 | $257.0K | $-29.99M | $-126.04 |
| 2015 | $257.0K | $-32.62M | $-214.08 |
| 2014 | $1.26M | $-4.23M | $-83.20 |
| 2013 | $16.86M | $-30.46M | $-1136.00 |
| 2012 | $16.84M | $-11.48M | $-580.80 |
Valuation
SCYXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·10d ago·Neutral
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…act Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Respons…
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D. JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K.
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
SCYNEXIS to Participate in Upcoming Investor Conferences JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of …
View source ↗
Earnings
Wed, Nov 4(in 3 weeks)
Consensus estimate $-0.72 per share
Typical surprise +26.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$0.63 vs $-0.51beat
- Mon, May 11$-3.36 vs $-0.80miss
- Wed, Mar 4$2.00 vs $1.01beat
- Wed, Nov 5$-1.36 vs $-1.60beat
- Thu, Aug 14$-1.12 vs $-1.52beat
- Fri, May 16$-0.88 vs $-1.55beat
Estimates and results for SCYX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SCYX officers and directors.
- Bought
- $393k
- Sold
- —
5 trades
0 trades
- Angulo Gonzalez Davidbought
- Angulo Gonzalez Davidbought
- Angulo Gonzalez Davidbought
- Taglietti Marcobought
- Sukenick Scottbought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SCYX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.